Trending...
- Can Declining Customer Satisfaction Help Curb Inflation?
- Nomorobo Assists Urgent FCC and Carrier Efforts to Crack Down on Auto Warranty Scam Robocalls
- Unprecedented Stress Levels Reveal Productivity Loss in the Billions; ASCEND Method Enters the Market
Prestigious CDMRP award will advance development of ORP100S as an inhaled treatment for acute and chronic respiratory diseases
SAN DIEGO - Michimich -- OrPro Therapeutics, Inc., a San Diego Johnson & Johnson JLABS alumni and 2022 SD CONNECT Cool Company, is pleased to announce that it has been awarded a Fiscal Year 2021 (FY21) Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development grant under the Congressionally Directed Medical Research Program (CDMRP) of the US Department of Defense. This $2.147M award entitled "Development of Monothiol Human Thioredoxin-1 (ORP100S) as an Inhaled Treatment for Acute Viral Lung Injury" involves OrPro researchers and collaborators at the Institute for Airway Sciences in the Icahn School of Medicine at Mount Sinai (New York, NY), Lovelace Biomedical (Albuquerque, NM), and KCAS Bioanalytical Services (Olathe, KS). Project advisors include innate immunity opinion leader Dr. Richard Ulevitch, Professor and former Chair of the Department of Immunology at Scripps Research; 3-D stem cell derived human lung organoid pioneer Dr. Ya-Wen Chen at Mount Sinai; and internationally recognized inhalation toxicology expert Dr. Jeffrey Tepper.
The objective of the grant-funded research is to understand the pharmacodynamic effect of ORP100S in vitro and in vivo for treatment of relevant viral diseases (COVID-19 and influenza), as well as to establish a validated bioanalytical method for the detection and quantification of ORP100S in plasma/serum and lung matrices from humans and non-clinical toxicology species. These objectives represent key ORP100S development milestones toward a US FDA Investigational New Drug (IND) filing and human clinical trials.
More on Michimich.com
"CDMRP funding is highly competitive. Our team is tremendously excited to be recognized by the Department of Defense for the potential of our drug platform to impact respiratory health by filling a critical gap in the prevention of lung injury associated with viral infection and inflammation," said Dr. Peter Heifetz, Founder, President and CEO of OrPro Therapeutics. "This award will enable us to rapidly advance ORP100S for multiple indications with high unmet medical need."
"Our 3-D human lung organoid system has been proven to accurately recapitulate respiratory viral infection and host responses, making it ideal for evaluation of the efficacy and mechanism of novel therapeutics. I am looking forward to working with Principal Investigator Dr. Heifetz and the project team to combine our in vitro human system with parallel in vivo studies in relevant animal infection models, said Dr. Ya-Wen Chen, Assistant Professor, Icahn School of Medicine at Mount Sinai. "This dual approach has great promise for enabling successful translation to clinical studies."
Thioredoxin
Secreted human thioredoxin (TRX) is a target-selective thiol-disulfide exchange enzyme that acts homeostatically to modulate inflammatory cytokine release, oxidative stress, and abnormal airway mucus viscoelasticity via regulatory interaction with extracellular cell-surface protein disulfides. TRX lowers inflammation in acute lung injury, and published studies show it can prevent viral pneumonia and increase survival in influenza-infected animal models. OrPro has developed the proprietary Theradux® platform of TRX derivatives optimized for extracellular delivery and function with increased half-life and decreased potential for intracellular uptake and off-target activity. Lead development candidate ORP100S is highly active extracellularly as a cell protectant without promoting cellular proliferation and is being advanced as an inhaled nebulized solution for treatment of acute and chronic obstructive/inflammatory airway diseases.
More on Michimich.com
About OrPro Therapeutics
OrPro Therapeutics, Inc is a privately held preclinical-stage company pioneering a novel biologic drug platform for treating severe respiratory, ophthalmic, and mucosal diseases. The company's differentiated approach targets both lung clearance and inflammation as well as obstructive/inflammatory disorders associated with non-respiratory mucosal surfaces in the body. Launched in 2013 with technology in-licensed from National Jewish Health, the leading US respiratory research center, the company has secured Series A financing and significant non-dilutive grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation with over $7M raised to date. For more information visit www.orprotherapeutics.com.
Contact
Peter Heifetz, Ph.D. OrPro Therapeutics, Inc. pheifetz@orprotherapeutics.com;
Media: Joleen Schultz, joleen@joleenschultzassociates.com; 760-271-8150
The objective of the grant-funded research is to understand the pharmacodynamic effect of ORP100S in vitro and in vivo for treatment of relevant viral diseases (COVID-19 and influenza), as well as to establish a validated bioanalytical method for the detection and quantification of ORP100S in plasma/serum and lung matrices from humans and non-clinical toxicology species. These objectives represent key ORP100S development milestones toward a US FDA Investigational New Drug (IND) filing and human clinical trials.
More on Michimich.com
- Wood Underwear® FW22 Introduces New Styles in Lounge
- Loxperts Inc. launches the first-ever on-demand freelancer marketplace dedicated to localization experts
- Agent Timothy Braue Awarded Prestigious "Premier Luxury Marketing Consultant" Certification
- Sterling Heights: New! Value Line Database
- Why should I use a company for Air Duct Cleaning in NJ
"CDMRP funding is highly competitive. Our team is tremendously excited to be recognized by the Department of Defense for the potential of our drug platform to impact respiratory health by filling a critical gap in the prevention of lung injury associated with viral infection and inflammation," said Dr. Peter Heifetz, Founder, President and CEO of OrPro Therapeutics. "This award will enable us to rapidly advance ORP100S for multiple indications with high unmet medical need."
"Our 3-D human lung organoid system has been proven to accurately recapitulate respiratory viral infection and host responses, making it ideal for evaluation of the efficacy and mechanism of novel therapeutics. I am looking forward to working with Principal Investigator Dr. Heifetz and the project team to combine our in vitro human system with parallel in vivo studies in relevant animal infection models, said Dr. Ya-Wen Chen, Assistant Professor, Icahn School of Medicine at Mount Sinai. "This dual approach has great promise for enabling successful translation to clinical studies."
Thioredoxin
Secreted human thioredoxin (TRX) is a target-selective thiol-disulfide exchange enzyme that acts homeostatically to modulate inflammatory cytokine release, oxidative stress, and abnormal airway mucus viscoelasticity via regulatory interaction with extracellular cell-surface protein disulfides. TRX lowers inflammation in acute lung injury, and published studies show it can prevent viral pneumonia and increase survival in influenza-infected animal models. OrPro has developed the proprietary Theradux® platform of TRX derivatives optimized for extracellular delivery and function with increased half-life and decreased potential for intracellular uptake and off-target activity. Lead development candidate ORP100S is highly active extracellularly as a cell protectant without promoting cellular proliferation and is being advanced as an inhaled nebulized solution for treatment of acute and chronic obstructive/inflammatory airway diseases.
More on Michimich.com
- Let's Finally Meet The Man That Fronts The Grammy Nominated Artist "Special Request Ft Rey T."
- Michigan Water Filtration Company Can Remove PFAS
- Automakers are Moving Towards More Sustainable Strategies
- Federal Defendants Acquitted of Conspiracy to Possess and Possession of 279 Kilos of Cocaine
- ADDING and REPLACING ODL, Inc. Acquires Second Quebec Company with Purchase of Robover, Expands Growth in North America
About OrPro Therapeutics
OrPro Therapeutics, Inc is a privately held preclinical-stage company pioneering a novel biologic drug platform for treating severe respiratory, ophthalmic, and mucosal diseases. The company's differentiated approach targets both lung clearance and inflammation as well as obstructive/inflammatory disorders associated with non-respiratory mucosal surfaces in the body. Launched in 2013 with technology in-licensed from National Jewish Health, the leading US respiratory research center, the company has secured Series A financing and significant non-dilutive grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation with over $7M raised to date. For more information visit www.orprotherapeutics.com.
Contact
Peter Heifetz, Ph.D. OrPro Therapeutics, Inc. pheifetz@orprotherapeutics.com;
Media: Joleen Schultz, joleen@joleenschultzassociates.com; 760-271-8150
Source: OrPro Therapeutics
Filed Under: Health, Government
0 Comments
Latest on Michimich.com
- Threat Report Shows Dramatic Uptick in Threat Activity with Exploits Growing Nearly 150%
- UnitedHealthcare Donates $1 Million to Nonprofits in Michigan
- Grammy Award Winning Singer, Songwriter and Producer David Longoria Joins the List of Artists at VANC Fest 2022
- O2 Investment Partners Announces Appointment of Josh Blumenstein
- Positive Powerful Women Gather to Promote Unity in the Grand Canyon State
- Serenity Movers Delivers First-Class Moving Services in NYC
- Local NJ Author Releases Debut Novel, Achieves Bestselling e-Book Status
- Safer Products Use Digital Engineering & Agile Processes
- Unprecedented Stress Levels Reveal Productivity Loss in the Billions; ASCEND Method Enters the Market
- Tech Luminary Adrian Cockcroft Joins OrionX as Partner
- Can Declining Customer Satisfaction Help Curb Inflation?
- Mike Morse Law Firm To Host Ninth Annual Project Backpack Event, Donations Surpass 250,000 Backpacks
- Nomorobo Assists Urgent FCC and Carrier Efforts to Crack Down on Auto Warranty Scam Robocalls
- Horizon Global Announces Review of Strategic Alternatives
- Habitat for Humanity partners with U.S. Department of Veterans Affairs to increase homeownership among Veterans
- Diedra Harrison-Greenaway launches new book titled: The Blueprint: A Guide Towards Cannabis Business Ownership
- Tarps Now Announces Informational Circular for use of Clear Vinyl Tarp Solutions
- Distinguished New York Trial Attorney and Author Donates Book Proceeds to NYU Cancer Research Center
- Veterans.Realty Launches FREE Business Directory for Military Veterans and Spouses
- Treat Yourself Right This Summer With LA's Best Massage Therapy for Serious Pain Relief Near You!